全文获取类型
收费全文 | 4363篇 |
免费 | 374篇 |
国内免费 | 2篇 |
出版年
2023年 | 16篇 |
2022年 | 32篇 |
2021年 | 151篇 |
2020年 | 72篇 |
2019年 | 76篇 |
2018年 | 114篇 |
2017年 | 94篇 |
2016年 | 153篇 |
2015年 | 240篇 |
2014年 | 280篇 |
2013年 | 328篇 |
2012年 | 413篇 |
2011年 | 363篇 |
2010年 | 249篇 |
2009年 | 204篇 |
2008年 | 274篇 |
2007年 | 249篇 |
2006年 | 220篇 |
2005年 | 179篇 |
2004年 | 196篇 |
2003年 | 188篇 |
2002年 | 161篇 |
2001年 | 28篇 |
2000年 | 25篇 |
1999年 | 43篇 |
1998年 | 38篇 |
1997年 | 29篇 |
1996年 | 22篇 |
1995年 | 21篇 |
1994年 | 23篇 |
1993年 | 26篇 |
1992年 | 17篇 |
1991年 | 18篇 |
1990年 | 19篇 |
1989年 | 12篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 15篇 |
1985年 | 7篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 15篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1974年 | 9篇 |
1969年 | 4篇 |
1965年 | 5篇 |
排序方式: 共有4739条查询结果,搜索用时 140 毫秒
61.
Francis J. Castellino Zhong Liang Patrick K. Davis Rashna D. Balsara Harsha Musunuru Deborah L. Donahue Denise L. Smith Mayra J. Sandoval-Cooper Victoria A. Ploplis Mark Walsh 《PloS one》2012,7(12)
To delineate the critical features of platelets required for formation and stability of thrombi, thromboelastography and platelet aggregation measurements were employed on whole blood of normal patients and of those with Bernard-Soulier Syndrome (BSS) and Glanzmann’s Thrombasthenia (GT). We found that separation of platelet activation, as assessed by platelet aggregation, from that needed to form viscoelastic stable whole blood thrombi, occurred. In normal human blood, ristocetin and collagen aggregated platelets, but did not induce strong viscoelastic thrombi. However, ADP, arachidonic acid, thrombin, and protease-activated-receptor-1 and -4 agonists, stimulated both processes. During this study, we identified the genetic basis of a very rare double heterozygous GP1b deficiency in a BSS patient, along with a new homozygous GP1b inactivating mutation in another BSS patient. In BSS whole blood, ADP responsiveness, as measured by thrombus strength, was diminished, while ADP-induced platelet aggregation was normal. Further, the platelets of 3 additional GT patients showed very weak whole blood platelet aggregation toward the above agonists and provided whole blood thrombi of very low viscoelastic strength. These results indicate that measurements of platelet counts and platelet aggregability do not necessarily correlate with generation of stable thrombi, a potentially significant feature in patient clinical outcomes. 相似文献
62.
Antoaneta Trendafilova Victoria Ivanova Miroslav Rangelov Milka Todorova Gulmira Ozek Suleyman Yur Temel Ozek Ina Aneva Ralitza Veleva Veselina Moskova‐Doumanova Jordan Doumanov Tanya Topouzova‐Hristova 《化学与生物多样性》2020,17(4)
Chlorogenic (5‐CQA), 1,5‐, 3,5‐, 4,5‐ and 3,4‐dicaffeoylquinic (DCQA) acids were identified and quantified in the methanol extracts of Inula oculus‐christi L., I. bifrons L., I. aschersoniana Janka var. aschersoniana, I. ensifolia L., I. conyza (Griess .) DC. and I. germanica L. by HPLC analysis. The amount of 5‐CQA varied from 5.48 to 28.44 mg/g DE and the highest content was detected in I. ensifolia. 1,5‐DCQA (4.05–55.25 mg/g DE) was the most abundant dicaffeoyl ester of quinic acid followed by 3,5‐DCQA, 4,5‐DCQA and 3,4‐DCQA. The extract of I. ensifolia showed the highest total phenolic content (119.92±0.95 mg GAE/g DE) and exhibited the strongest DPPH radical scavenging activity (69.41±0.55 %). I. bifrons extract was found to be the most active sample against ABTS.+ (TEAC 0.257±0.012 mg/mL) and the best tyrosinase inhibitor. The studied extracts demonstrated a low inhibitory effect towards acetylcholinesterase and possessed low cytotoxicity in concentration range from 10 to 300 μg/mL toward non‐cancer (MDCK II) and cancer (A 549) cells. 相似文献
63.
64.
65.
66.
67.
68.
Vélez Debora E. Mestre-Cordero Victoria E. Hermann Romina Perego Juliana Harriet Sofia Fernandez-Pazos María de las Mercedes Mourglia Julieta Marina-Prendes M. Gabriela 《Journal of physiology and biochemistry》2020,76(1):85-98
Journal of Physiology and Biochemistry - The cardioprotective activity of rosuvastatin (R) is yet to be known. The objective of this study was to research whether R perfusion before global ischemia... 相似文献
69.
Victoria A. Hassebroek Hyewon Park Nootan Pandey Brooklyn T. Lerbakken Vasilisa Aksenova Alexei Arnaoutov Mary Dasso Yoshiaki Azuma 《Molecular biology of the cell》2020,31(23):2537
Proper chromosome segregation is essential for faithful cell division and if not maintained results in defective cell function caused by the abnormal distribution of genetic information. Polo-like kinase 1–interacting checkpoint helicase (PICH) is a DNA translocase essential for chromosome bridge resolution during mitosis. Its function in resolving chromosome bridges requires both DNA translocase activity and ability to bind chromosomal proteins modified by the small ubiquitin-like modifier (SUMO). However, it is unclear how these activities cooperate to resolve chromosome bridges. Here, we show that PICH specifically disperses SUMO2/3 foci on mitotic chromosomes. This PICH function is apparent toward SUMOylated topoisomerase IIα (TopoIIα) after inhibition of TopoIIα by ICRF-193. Conditional depletion of PICH using the auxin-inducible degron (AID) system resulted in the retention of SUMO2/3-modified chromosomal proteins, including TopoIIα, indicating that PICH functions to reduce the association of these proteins with chromosomes. Replacement of PICH with its translocase-deficient mutants led to increased SUMO2/3 foci on chromosomes, suggesting that the reduction of SUMO2/3 foci requires the remodeling activity of PICH. In vitro assays showed that PICH specifically attenuates SUMOylated TopoIIα activity using its SUMO-binding ability. Taking the results together, we propose a novel function of PICH in remodeling SUMOylated proteins to ensure faithful chromosome segregation. 相似文献
70.
Robert Mason Helen C. Dearden Bella Nguyen Jennifer A. Soon Jessica Louise Smith Manreet Randhawa Andrew Mant Lydai Warburton Serigne Lo Tarek Meniawy Alexander Guminski Phillip Parente Sayed Ali Andrew Haydon Georgina V. Long Matteo S. Carlino Michael Millward Victoria G. Atkinson Alexander M. Menzies 《Pigment cell & melanoma research》2020,33(2):358-365
The combination of ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. We explore the safety and efficacy of this treatment in routine clinical practice, particularly in the setting of serine/threonine‐protein kinase B‐Raf (BRAF)‐targeted therapy. Consecutive patients with unresectable stage IIIC/IV melanoma commenced on ipilimumab and nivolumab across 10 tertiary melanoma institutions in Australia were identified retrospectively. Data collected included demographics, response and survival outcomes. A total of 152 patients were included for analysis, 39% were treatment‐naïve and 22% failed first‐line BRAF/MEK inhibitors. Treatment‐related adverse events occurred in 67% of patients, grade 3–5 in 38%. The overall objective response rate was 41%, 57% in treatment‐naïve and 21% in BRAF/MEK failure patients. Median progression‐free survival was 4.0 months (95% CI, 3.0–6.0) in the whole cohort, 11.0 months (95% CI, 6.0‐NR) in treatment‐naïve and 2.0 months (95% CI, 1.4–4.6) in BRAF/MEK failure patients. The combination of ipilimumab and nivolumab can be used safely and effectively in a real‐world population. While first‐line efficacy appears comparable to trial populations, BRAF‐mutant patients failing prior BRAF/MEK inhibitors show less response. 相似文献